{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:07:12Z","timestamp":1778274432207,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1053\/ajkd.2002.35758","type":"journal-article","created":{"date-parts":[[2002,9,25]],"date-time":"2002-09-25T14:38:22Z","timestamp":1032964702000},"page":"e16.1-e16.6","source":"Crossref","is-referenced-by-count":71,"title":["Gemcitabine-associated hemolytic-uremic syndrome"],"prefix":"10.1053","volume":"40","author":[{"given":"Roland B.","family":"Walter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Joerger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard C.","family":"Pestalozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/ajkd.2002.35758_bib1","first-page":"388","article-title":"Pharmacology of cancer chemotherapy: Antimetabolites","author":"Chu","year":"2001"},{"key":"10.1053\/ajkd.2002.35758_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00001813-199803000-00001","article-title":"Gemcitabine\u2014a safety review","volume":"9","author":"Aapro","year":"1998","journal-title":"Anticancer Drugs"},{"key":"10.1053\/ajkd.2002.35758_bib3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/00001813-199707000-00005","article-title":"Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer","volume":"8","author":"Cortes-Funes","year":"1997","journal-title":"Anticancer Drugs"},{"issue":"suppl 10","key":"10.1053\/ajkd.2002.35758_bib4","first-page":"32","article-title":"Gemcitabine safety overview","volume":"23","author":"Green","year":"1996","journal-title":"Semin Oncol"},{"issue":"suppl 6","key":"10.1053\/ajkd.2002.35758_bib5","first-page":"627","article-title":"Safety profile of gemcitabine","volume":"6","author":"Tonato","year":"1995","journal-title":"Anticancer Drugs"},{"key":"10.1053\/ajkd.2002.35758_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00873232","article-title":"Phase II trial of gemcitabine (2,2\u2032-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas","volume":"12","author":"Casper","year":"1994","journal-title":"Invest New Drugs"},{"key":"10.1053\/ajkd.2002.35758_bib7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1046\/j.1523-1755.2001.060003831.x","article-title":"Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura","volume":"60","author":"Ruggenenti","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2002.35758_bib8","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<2023::AID-CNCR21>3.0.CO;2-2","article-title":"A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy","volume":"85","author":"Fung","year":"1999","journal-title":"Cancer"},{"issue":"suppl 10","key":"10.1053\/ajkd.2002.35758_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0093-7754(01)80011-7","article-title":"Gemcitabine in ovarian cancer","volume":"28","author":"Orlando","year":"2001","journal-title":"Semin Oncol"},{"issue":"suppl 7","key":"10.1053\/ajkd.2002.35758_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0093-7754(01)90274-X","article-title":"The current role of gemcitabine in ovarian cancer","volume":"28","author":"Ozols","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1053\/ajkd.2002.35758_bib11","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/jnci\/89.24.1895","article-title":"Gemcitabine-induced hemolytic uremic syndrome: A case report","volume":"89","author":"Brodowicz","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/ajkd.2002.35758_bib12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0272-6386(99)70194-0","article-title":"Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine","volume":"33","author":"Flombaum","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.35758_bib13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1159\/000013525","article-title":"Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy","volume":"19","author":"Lhotta","year":"1999","journal-title":"Am J Nephrol"},{"key":"10.1053\/ajkd.2002.35758_bib14","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/ajkd.2002.35758_bib15","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1023\/A:1008467914836","article-title":"Hemolytic-uremic syndrome caused by gemcitabine","volume":"9","author":"Nackaerts","year":"1998","journal-title":"Ann Oncol"},{"issue":"suppl S","key":"10.1053\/ajkd.2002.35758_bib16","first-page":"274A","article-title":"The association of gemcitabine and hemolytic uremic syndrome: A case report","volume":"46","author":"Berk","year":"1998","journal-title":"J Invest Med"},{"key":"10.1053\/ajkd.2002.35758_bib17","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1093\/ndt\/14.10.2523","article-title":"Haemolytic uraemic syndrome after gemcitabine treatment for pancreatic carcinoma","volume":"14","author":"Choi","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2002.35758_bib18","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S","article-title":"A phase II study of gemcitabine in patients with malignant pleural mesothelioma","volume":"85","author":"van Meerbeeck","year":"1999","journal-title":"Cancer"},{"key":"10.1053\/ajkd.2002.35758_bib19","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/sj.bjc.6690242","article-title":"Elevated reticulocyte count\u2014a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: A case report","volume":"79","author":"Serke","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1053\/ajkd.2002.35758_bib20","first-page":"2459","article-title":"Locoregional\/systemic chemotherapy of locally advanced\/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers","volume":"19","author":"Klapdor","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1053\/ajkd.2002.35758_bib21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00001813-199907000-00004","article-title":"Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine","volume":"10","author":"Gross","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1053\/ajkd.2002.35758_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1055\/s-2000-7441","article-title":"42-j\u00e4hriger Patient mit h\u00e4molytisch-ur\u00e4mischem Syndrom unter Gemcitabin-Therapie eines Adenokarzinoms der Leber. H\u00e4molytisch-ur\u00e4misches Syndrom und Gemcitabin","volume":"38","author":"Eckel","year":"2000","journal-title":"Z Gastroenterol"},{"key":"10.1053\/ajkd.2002.35758_bib23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.2001.02795.x","article-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma","volume":"113","author":"Dumontet","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/ajkd.2002.35758_bib24","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1200\/JCO.1994.12.8.1535","article-title":"Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study","volume":"12","author":"Abratt","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/ajkd.2002.35758_bib25","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/JCO.1994.12.9.1821","article-title":"Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study","volume":"12","author":"Anderson","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/ajkd.2002.35758_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200124010-00003","article-title":"Anticancer drug-induced kidney disorders","volume":"24","author":"Kintzel","year":"2001","journal-title":"Drug Saf"},{"key":"10.1053\/ajkd.2002.35758_bib27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.1962.tb06541.x","article-title":"Microangiopathic haemolytic anaemia: The possible role of vascular lesions in pathogenesis","volume":"8","author":"Brain","year":"1962","journal-title":"Br J Haematol"},{"key":"10.1053\/ajkd.2002.35758_bib28","first-page":"140","article-title":"Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome","volume":"34","author":"Gordon","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1053\/ajkd.2002.35758_bib29","first-page":"161","article-title":"Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents","volume":"24","author":"Murgo","year":"1987","journal-title":"Semin Hematol"},{"key":"10.1053\/ajkd.2002.35758_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ajh.2830440115","article-title":"Hemolytic uremic syndrome developing during remission of acute myelomonocytic leukemia","volume":"44","author":"Okumura","year":"1993","journal-title":"Am J Hematol"},{"key":"10.1053\/ajkd.2002.35758_bib31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ajh.2830210309","article-title":"Thrombotic thrombocytopenic purpura subsequent to acute myelogenous leukemia chemotherapy","volume":"21","author":"Byrnes","year":"1986","journal-title":"Am J Hematol"},{"key":"10.1053\/ajkd.2002.35758_bib32","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry","volume":"7","author":"Lesesne","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1053\/ajkd.2002.35758_bib33","first-page":"159","article-title":"Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome","volume":"34","author":"Kwaan","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1053\/ajkd.2002.35758_bib34","first-page":"S45","article-title":"Hemolytic uremic syndrome\/thrombotic thrombocytopenic purpura: Pathophysiology and treatment","volume":"64","author":"Neild","year":"1998","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/ajkd.2002.35758_bib35","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/1097-0142(19861001)58:7<1428::AID-CNCR2820580709>3.0.CO;2-J","article-title":"A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma","volume":"58","author":"Sheldon","year":"1986","journal-title":"Cancer"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638602500196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638602500196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T11:23:33Z","timestamp":1554809013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638602500196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["S0272638602500196"],"URL":"https:\/\/doi.org\/10.1053\/ajkd.2002.35758","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}